



King's Research Portal

Document Version Peer reviewed version

Link to publication record in King's Research Portal

Citation for published version (APA):

Abela, E. C., Pawley, A. D., Tangwiriyasakul, C., Yaakub, S. N., Chowdhury, F. A., Barker, G. J., Elwes, R. D. C., Brunnhuber, F., & Richardson, M. P. (in press). Slower alpha rhythm associates with poorer seizure control in epilepsy. Annals of Clinical and Translational Neurology.

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Download date: 09. Jan. 2025

Slower alpha rhythm associates with poorer seizure control in epilepsy

*Eugenio Abela, MD^{1,3}; *Adam D. Pawley, PhD²; Chayanin Tangwiriyasakul, PhD¹, Siti Nurbaya Yaakub, PhD^{1,4},

Fahmida A. Chowdhury, MRCP, PhD⁵, Robert D.C. Elwes, FRCP, MD³, Franz Brunnhuber, MD³, Mark P. Richardson,

FRCP, PhD^{1,3}

1. Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's

College London, London, UK

2. Social, Genetic and Developmental Psychiatry Research Center, Institute of Psychiatry, Psychology and

Neuroscience, King's College London, London, UK

3. Department of Clinical Neurophysiology, King's College Hospital NHS Foundation Trust, London, UK

4. School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK

5. National Hospital for Neurology and Neurosurgery, UCL Hospitals NHS Foundation Trust, London, UK

*These authors contributed equally

Corresponding author: Professor Mark P. Richardson

Corresponding author's address: Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology &

Neuroscience, King's College London, 125 Coldharbour Lane, London SE5 9NU, United Kingdom

Corresponding author's phone and fax: phone +44 (0) 2078485364, fax +44 (0) 2078485914

Corresponding author's e-mail address: mark.richardson@kcl.ac.uk

Running head: Slow alpha rhythm and seizure control in epilepsy

Number of words in abstract: 249

Number of words in main text: Introduction 455; Discussion 1215; Body of manuscript 4474.

Number of figures: 2

Number of tables: 2

ABSTRACT

Objective: Slowing and frontal spread of the alpha rhythm have been reported in multiple epilepsy syndromes. We investigated whether these phenomena are associated with seizure control.

Methods: We prospectively acquired resting-state EEG in 63 patients with focal and idiopathic generalized epilepsy (FE and IGE) and 39 age- and gender-matched healthy subjects. Patients were divided into good and poor (≥ 4 seizures / 12 months) seizure control groups based on self-reports and clinical records. We computed spectral power from 20-second EEG segments during eyes-closed wakefulness, free of interictal abnormalities, and quantified power in high and low alpha bands. Analysis of covariance and post-hoc t-tests were used to assess group differences in alpha-power shift across all EEG channels. Permutation-based statistics were used to assess the topography of this shift across the whole scalp.

Results: Compared to healthy subjects, patients showed a statistically significant shift of spectral power from high- to low-alpha frequencies (effect size g = 0.78 [95% confidence interval 0.43,1.20]). This alpha-power shift was driven by patients with poor seizure control in both FE and IGE (g = 1.14, [0.65,1.74]), and occurred over midline frontal and bilateral occipital regions. IGE exhibited less alpha power shift compared to FE over bilateral frontal regions (g = -1.16 [-0.68, -1.74]). There was no interaction between syndrome and seizure control. Effects were independent of antiepileptic drug load, time of day, or subgroup definitions.

Interpretation: Alpha slowing and anteriorisation are a robust finding in patients with epilepsy and might represent a generic indicator of seizure liability.

INTRODUCTION

The human alpha rhythm is a prominent oscillatory electroencephalographic signal seen over occipital recording sites during relaxed, eyes-closed wakefulness. It is thought to arise through cortico-thalamic interactions, and to possibly reflect top-down processes that subtend a vast number of cognitive operations, in particular attention and working memory¹. The importance of the alpha rhythm is underscored by its alterations in neurological disease, where it typically slows down and loses its characteristic anterior-to-posterior gradient - changes that are usually commensurate with clinical severity and therefore useful to monitor neurological dysfunction².

These alterations of alpha, which are often seen over longer stretches of the electroencephalogram (EEG), are considered to be the hallmark of diffuse cortical-subcortical neuropathology, such as metabolic or neurodegenerative diseases, but they have been found in epilepsy as well. In fact, studies conducted during the first decades of EEG research found conspicuous alpha rhythm alterations in epilepsy patients; specifically, they reported that both power and topography of the alpha rhythm were shifted: power from higher (8-13 Hz) to lower (6-9 Hz) frequencies, and topography from occipital to frontal sites^{3,4}. Subsequent quantitative EEG studies confirmed these alterations in a wide variety of focal epilepsy (FE) and idiopathic (or genetic) generalized epilepsy (IGE) syndromes, and have identified them in unaffected first-degree IGE relatives and in drug-naïve patients as well⁵⁻¹⁰. The cause of this phenomenon and its clinical relevance remain poorly understood.

Because alpha rhythm alterations have been reported in such a disparate variety of epilepsy syndromes, they might simply reflect an unspecific byproduct of disease. Alternatively, they could point to shared neurobiological substrates for seizure generation. Although this might seem counterintuitive, given the multitude of insults and genetic mutations that can lead to seizures, a wealth of neuroimaging studies now supports the idea that icto- and epileptogenic mechanisms ultimately converge on a set of large-scale neural networks, in which thalamus and midline frontal and parietal cortices play an important role, even if they do not contain the seizure focus¹¹. Alpha alterations could therefore reflect pathological resting-state dynamics of this core network, and its liability to seizures. In fact, our group has previously shown that EEG networks from IGE patients show increased functional connectivity in low alpha frequencies¹², which associate with an increased propensity to generate seizure-like oscillations¹³. Does alpha slowing therefore indicate that the brain is operating closer to seizure threshold?

To address this question, we quantitatively assessed the distribution of alpha power between high and low frequency bands in resting-state EEG recordings of healthy subjects (HS), and FE and IGE patients with good and poor

PAGE 4

seizure control. We hypothesized that seizure control, but not epilepsy type or AED load, would determine the degree of alpha-power shift and its topography, suggesting shared ictogenic mechanisms across epilepsy syndromes.

METHODS

Participants

We analyzed data from 102 subjects investigated at King's College Hospital (KCH), London, between 2008 and 2015: 39 were healthy volunteers recruited through a local volunteer database, and 63 were patients with epilepsy (44 outpatients and 19 inpatients). Patients were recruited from KCH and collaborating hospitals, and included if they were over 18 years of age and had a definite diagnosis of epilepsy made by an experienced epileptologist on the basis of clinical presentation, EEG, and MRI. Diagnosis and classification were made in accordance with the International League Against Epilepsy (ILAE) 2017 classification of epilepsies and seizures^{14,15}. All controls and 9 IGE patients have been included in previous studies^{12,16}.

We divided patients into subgroups based on clinical presentation (IGE versus FE syndromes) and their level of seizure control, which we determined from seizure self-reports. This information was corroborated with clinical notes and electronic patient records whenever possible. We defined good seizure control (GSC) as fewer than four seizures of any type during the 12 months prior to study inclusion, and poor seizure control (PSC) otherwise. We also verified that no patient had had a seizure 24hr prior to EEG recording.

This study was approved by the KCH research ethics committee (ref. 08/H0808/157) and the Bromley research ethics committee (ref. 12/LO/2030). All participants gave written informed consent before enrolment.

Clinical data

We collected the following variables: gender, age, disease duration, syndrome type and lateralization, seizure types and frequency over 12 months, AED number and dosage, total AED load, and the presence of potentially epileptogenic MRI lesions. Total AED load was calculated by taking, for each drug, the ratio between its prescribed daily dose, and the defined daily dose (as determined by the WHO Collaborating Centre for Drug Statistics Methodology, http://www.whocc.no/atc ddd index/.) and then summing over all AED¹⁷.

EEG recordings

Ten minutes of awake EEG data were recorded on a NicoletOne system (Viasys Health Care, San Diego, California, USA) at 256 Hz from 19 channels positioned according to the international 10–20 system, with two reference electrodes attached to the ear lobes. The same EEG technologist performed all healthy subject and outpatient measurements, using

the same recording room and system for all participants. Inpatient EEGs were performed by a variety of staff of the epilepsy monitoring unit at KCH, according to clinical schedules. If participants consented, hyperventilation and photic stimulation were carried out.

EEG visual analysis

Three EEG-trained neurologists (FC, RE and FB) reviewed all EEGs and noted the following phenomena: presence of focal interictal epileptiform discharges (IED), generalized spike-wave discharges (GSWD), focal slowing, and normal variants. FC, RE and AP then selected two segments of 20 seconds of eyes-closed, awake EEG from each participant for subsequent analysis, which had to be free of large movement artefacts, epileptiform discharges, and signs of drowsiness or sleep. The first segment was used for the main analyses described below, the second was held out for control analyses. Data review and selection were done before data analysis. Further data analysis was carried out by EA, who was not involved in selection of EEG segments.

EEG power spectrum

EEG data were processed using Fieldtrip (Version 20171203, http://www.ru.nl/neuroimaging/fieldtrip)¹⁸ running on MATLAB (R2016b, The MathWorks, Inc., Natick, Massachusetts, United States). EEG segments were first rereferenced to a common average. We then calculated the power spectra of each segment using a Hanning-tapered fast Fourier transform (FFT). To this end, each segment was cut into a series of 1 second epochs with 90% overlap, demeaned, multiplied with the Hanning-taper, and zero-padded before computing the FFT. Power was calculated by squaring the modulus of the Fourier coefficients for each channel from 2 to 20 Hz in steps 1 Hz, and then normalized against total power for each channel. We chose this frequency range because it provided a broad overview of frequency bands commonly used in the literature, while avoiding very low frequency drifts and eye movements (<2 Hz), as well as muscle artefacts (>20 Hz)¹⁹. To test our hypotheses, we focused on the low-alpha (6-9 Hz) and high-alpha band (10-11 Hz)²⁰. This choice was motivated by band-definitions used in previous work from our group^{12,13}.

Statistical analysis

Clinical data were analyzed using JASP (Version 0.8.6, https://jasp-stats.org/) or SPSS (Version 24, IBM UK, London). We report continuous variables as mean \pm SD (range) and binary variables as proportions. We used the Shapiro-Wilk test

to assess deviations from normality. If assumptions were met, we compared means using unpaired t-tests, else we applied the Mann-Whitney U-test (or the Kruskal-Wallis test in the case of 3 groups). We compared proportions using the χ^2 -test or Fisher's exact test if the number of observations in any cell was equal or less than five.

The analysis of EEG power spectra had three aims: first, to confirm that there was a shift in the alpha-power spectrum from higher to lower frequencies as previously reported, second, to test whether this effect was driven by patients with poor seizure control, over and above syndrome classifications, and third, to assess whether the alpha-power shift occurred not only over occipital electrodes, where the alpha rhythm usually predominates, but over frontal electrodes as well. To simplify calculations, we defined the "alpha-power shift" as our outcome variable, i.e. the ratio of average power in the low-alpha power (6-9 Hz) over average power in the high-alpha (10-11 Hz):

$$Alpha-power$$
 $shift=rac{\mu_{Low-alpha\,power}}{\mu_{High-alpha\,power}}$

This measure increases if power in low-alpha frequencies increases, and will decrease otherwise. Collapsing over multiple frequencies and using a ratio has the advantage of reducing the number of multiple comparisons.

We performed all analyses both on grand-average power spectra and on scalp topographies. For the grand-average analyses, we averaged the power spectra across all channels and then calculated the power shift as above. This yielded one value per subject, i.e. a measure of global alpha-power shift without topographical information. Statistical analysis was then carried out in JASP statistical software using these values as dependent variable. We first computed a one-way between-subjects ANCOVA to test for differences in alpha-power shift between groups, with age and gender serving as covariates (which were included because of their known effects on EEG power spectra)²¹. Other clinical covariates were omitted because they were confounded with group assignment (i.e. only patients were treated with AEDs), and thus would have reduced model degrees of freedom without explaining clinically meaningful differences. We assessed the equality of variances using Levene's test, and the assumption of the homogeneity of regression slopes by modelling interaction terms between the group variable and each covariate. Furthermore, we inspected Q-Q plots of residuals to assess their departure from normality. We then used an F-test to determine the main effect of group, and post-hoc *t*-tests to assess the difference between the three subgroups. We next conducted a 2 x 2 between-subjects factorial ANCOVA on the patient data only, with the first factor syndrome (FE or IGE) and the second factor seizure

control (GSC or PSC), with age, gender and total AED load serving as covariates. AED load has been shown to increase low frequency power in previous patient studies^{5,22}; it was thus essential to include it as a covariate in here. Assumptions checks and statistical tests were conducted as above. We used a significance threshold of p < .05, family-wise error (FWE) corrected for multiple comparisons (Bonferroni).

For the topographic analyses, we calculated the alpha-power shift for each channel individually, and then linearly interpolated these values to produce, for each subject, a 2D scalp map on a regular 32 x 32 mm spatial grid²³. Maps were then smoothed with an 8 x 8 mm² Gaussian kernel to account for the relatively sparse spatial sampling²³. Statistics on these maps were carried out with Permutation Analysis of Linear Models (PALM, version alpha109, https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/PALM)²⁴. We calculated pair-wise comparisons between (1) healthy subjects and all patients, (2) GSC and PSC patients, and (3) IGE and FE patients, using unequal variances t-test at each map element (or voxel), with age and gender serving as covariates for all models, and AED load as an additional covariate for between-patient comparisons. This yielded one T-map per comparison (we did not recalculate the F-tests on spatial maps to avoid redundancy). To assess statistical significance without distributional assumptions, we ran permutations tests, i.e. recalculated T-maps after shuffling subjects between groups, using the Freedman-Lane algorithm to account for the presence of covariates (10'000 permutations)²⁴. We set the significance threshold at p<.05, FWE-corrected based on the empirical t-value distribution derived from permutations.

To quantify effect sizes, we derived η^2 and Hedge's g for all F- and t-tests, respectively. Hedge's g has the same interpretation as Cohen's d, but is less biased in the presence of unequal sample sizes²⁵. We used η^2 as provided from JASP output, and calculated Hedge's g using the Measure of Effect Size toolbox (https://github.com/hhentschke/measures-of-effect-size-toolbox).

Control analyses

We conducted a number of control analyses to rule out confounds (see supplemental materials). These included (1) repeating the analyses above using individual alpha frequency (IAF) instead of alpha-power shift, (2) assessing whether comparable effects could be reproduced in a second data segment of the same EEG recording, (3) testing two alterative seizure-control stratifications, i.e. grouping patients according to whether they had no versus any seizures and according to a median split, (4) testing a direct correlation between seizure frequency and alpha-power shift, without subgroup dichotomization, (5) investigating circadian influences by comparing EEG recording times between groups, (6) checking

for potential effects of specific AEDs, if their load varied between groups, and (7) repeating the topographical analysis in non-lesional epilepsy syndromes to rule out that spatial alterations were an epiphenomenon of structural damage.

Classification analysis

Post hoc, we also explored whether alpha-power shifts could be used to predict subject-wise seizure control and used a 10-fold cross-validated linear discriminant analysis (LDA) to classify GSC and PSC patient data²⁶.

Data visualizations and resources

Plots of average spectra were generated with Gramm²⁷, high-resolution scalp topographies with SPM12 and Fieldtrip. Code and processed data are publicly available on https://osf.io/f2vya/. Raw EEG data can be obtained from the senior author upon request.

RESULTS

Clinical features

Table 1 summarises clinical data. There were more patients with a focal syndrome in the PSC compared to the GSC group. In keeping with this finding, PSC patients suffered more often from focal impaired awareness seizures, presented more focal IED, and more often MRI lesions. On the other hand, GSC patients were treated on average with higher doses of Lamotrigine compared to PSC patients. Photic stimulation and hyperventilation were performed only in a subset of patients and were inconspicuous in all of them (photic: 15 GSC, 14 PSC; hyperventilation: 12 GSC, 13 PSC).

Alpha-power shifts occur in patients with poor seizure control in both focal and generalized epilepsy syndromes, and do not depend on age, gender, or drug load

Visual inspection of average power spectra revealed a shift of EEG power from high- to low-alpha in all subgroup comparisons (Fig. 1A-C). To quantify these observations, we first calculated a one-way between-subjects ANCOVA comparing HS against both PSC and GSC, with age and gender serving as covariates. Levene's test was significant (p<.001); this was ameliorated after taking the binary log of the alpha-power shift (p = .268). Q-Q-plot of residuals showed no departure from normality, and tests for the assumption of homogeneity of regression slopes revealed no interaction between covariates and groups (gender x group, p = .307, age x group, p = .520), indicating that model assumptions were met. After partialling out variance associated with age and gender, there was a statistically significant difference in alpha-power shift between groups, F(2,97) = 17.20, p<.001, p = 0.26. Planned contrasts revealed that patients presented a clear alpha-power shift compared to HS (M = -0.32, SD = 0.48), t(100) = 3.62, p<.001, g = 0.78, 95% CI [0.43,1.20]. This effect was driven by PSC patients (M = 0.28, SD = 0.48), which had a substantially larger shift than the GSC group (M = -0.24, SD = 0.41), t(61) = 4.23, p<.001, g = 1.14, 95%CI [0.65,1.74] (Fig. 1D).

We next assessed whether alpha-power shifts were a unique feature of PSC patients, regardless of the underlying syndrome. To do so, we conducted a 2 x 2 between-subjects factorial ANCOVA with the first factor syndrome (FE or IGE) and the second factor seizure control (GSC or PSC), with age, gender and total AED load serving as covariates. Again, tests for homogeneity of variances and regression slopes were not significant (all p > .05). We found statistically significant main effects of syndrome, F(1,59) = 7.74, p = .007, $\eta^2 = 0.099$, and seizure control, F(1,57) = 11.65, p = .001, $\eta^2 = 0.15$, but no statistically significant interaction, F(1,57) = 0.477, p = .492, $\eta^2 = 0.006$. Planned contrasts indicated that FE patients (M = 0.27, SD = 0.48) presented a larger alpha-power shift than IGE patients (M = 0.27, SD = 0.48) presented a larger alpha-power shift than IGE patients (M = 0.27).

0.20, SD = 0.45), t(61) = 2.78, p = .007, g = 1.16 [95%CI 0.67,1.74]. Within each syndrome category, PSC patients showed significantly larger shifts than their GSC counterparts, t(61) = 3.41, p = .001, g = 1.12 [95%CI 0.64,1.70] (Fig. 1E).

Alpha-power shifts are topographically extended, indicating a forward spread of low-alpha power

We next asked whether there was a topographical shift, i.e. a forward spread of the low-frequency alpha rhythm, as well. To do so, we calculated pairwise comparisons between groups using topographical maps of alpha-power shift and assessed their significance with permutation tests.

This analysis revealed that alpha-power was shifted in patients towards lower frequencies both frontally and occipitally, with a maximum over the right occipital region (Table 2, Fig. 2A). Again, this effect was driven by PSC patients, who presented an increased alpha-power shift that broadly covered the entire scalp, with peaks over central and bilateral occipital regions (Table 2, Fig. 2B). The comparison between IGE and FE patients revealed that FE patients had more alpha-power shift over both frontal regions, with a maximum on the right (Table 2, Fig. 2C).

Control analyses confirm a general slowing down of the alpha-rhythm, and rule out data selection or acquisition biases as alternative explanations

We conducted a number of control analyses to test the robustness of our findings to methodological choices. Full results are summarised in the supplemental materials. Briefly, comparing patients on the basis of IAF instead of power lead to qualitatively similar results, as did analysing a second data segment from the same recording. Furthermore, PSC patients were always more shifted compared to GSC patients, even when using alternative dichotomisation rules or accounting for patients on lamotrigine (which showed between-group dosage differences). Of note, we also found a significant correlation between individual alpha-power shift and seizure frequency, particularly over frontal recording sites, thus corroborating the subgroup analyses above. In addition, there were no significant differences in terms of EEG recording times, ruling out circadian confounds. Finally, both focal PSC patients without discernible brain lesions, as well as IGE-PSC patients, which are non-lesional per definition, showed anteriorisation of low alpha-power.

These analyses thus show that findings were fairly consistent over a number of approaches, and robust to confounds.

Alpha-power shift can discriminate seizure control subgroups

An exploratory LDA with 10-fold cross-validation achieved the following performance parameters (mean \pm SD [95% CI]): sensitivity of 71.2 \pm 3.9% [63.5%, 78.8%], specificity of 79.6 \pm 2.2% [75.2%, 83.9%], and AUC of 78.8 \pm 1.0% [67.7%, 89.8%], which was highly significant (z-test, p = 1.7 * 10-7).

DISCUSSION

In this study, we show that the power spectrum of the alpha rhythm is shifted towards lower frequencies in epilepsy patients with poor seizure control, in both focal and generalized epilepsy syndromes. Furthermore, we demonstrate that this effect extends from occipital to frontal regions, and is more pronounced in FE patients. Our study took major steps to control for methodological confounds. Firstly, we explicitly included age, gender and AED load as covariates in all our models, and used permutation-based statistics for assessing scalp EEG topographies, thus achieving adequate false-positive control with few assumptions. Secondly, we confirmed that our results were robust to data selection procedures, patient subgroup definitions, circadian effects, and different outcome metrics (power versus frequency). Finally, we could show that spatial alterations in alpha-power occurred also in non-lesional epilepsy syndromes. Taken together, the present analyses indicate that space-frequency alterations of the alpha rhythm strongly associate with increased seizure liability in common epilepsy syndromes, whether generalized or focal.

The observation that alpha rhythm is altered in epilepsy is not new. In fact, a number of historic and contemporaneous studies have described slower alpha rhythms in heterogeneous (focal and generalized) epilepsy cohorts, sometimes pointing out the anteriorisation of topography as well^{3-6,8}. Capitalising on recent advances in permutation statistics and topographical EEG analysis^{23,24}, our study advances this line of research by showing that this seemingly ubiquitous phenomenon is likely related to seizure liability: significant alpha-power shifts were present in all patients when compared to healthy controls, but were specifically driven by patients with poor seizure control. Effect sizes were moderate to very large, indicating that these findings were not subtle in quantitative terms. Importantly, analyses were done on data segments that were considered normal by experts, suggesting that on-going background EEG rhythms contain clinically valuable information that cannot be gleaned from visual analysis alone. This information that could have practical utility: a post-hoc, exploratory classification analysis suggests that patients with poor versus good seizure-control might be identified at the individual level with fair accuracy (AUC ~0.8) on the basis of alpha-power shifts alone. This performance is comparable to a recent report that used highly optimised classifiers on resting-state

EEG data to discriminate between epilepsy patients and neurological controls⁵, although larger, multi-center data sets are certainly needed to confirm this result.

Another important aspect is that alpha-power shifts were present in equal measure both in FE and IGE syndromes, i.e., there was no significant syndrome-by-seizure control interaction (parallel slopes in Fig 1E). This means that, independent of the underlying clinical syndrome, patients with poor seizure control exhibit more alpha-slowing and frontal spread than well-controlled patients, although power in FE patients was more shifted overall (Fig. 1E), and there were clear topographic differences of this effect between IGE and FE patients (Fig. 2C). These findings suggest that alpha-rhythm alterations might reflect seizure-promoting mechanisms that are generic to all common epilepsy types, but additionally undergo syndrome-specific modulation.

The neurobiological basis of these observations is at present unclear, but could relate to the underlying severity and extent of cortical dysfunction. Evidence from different lines of research gives strength to the idea that there are indeed generic disease mechanisms or processes that cut across epilepsy phenotypes, and that might affect oscillatory EEG features. For instance, it is well-known from clinical experience that multiple pathologies lead to similar seizure behavior, a phenomenon which can be explained by the involvement of large-scale networks¹¹. Indeed, a recent MRI study has shown that common epilepsy syndromes share structural abnormalities most prominently in right thalamus and precentral gyri²⁸, and an overview of recent neuroimaging studies suggest that medial frontal cortices are key nodes in epilepsy-related networks as well²⁹. Interestingly, the topographies of alpha-power shift we uncovered in PSC patients are broadly reminiscent of those associated with mid-frontal theta oscillations (4-7 Hz) seen during cognitive tasks; these are commonly thought to arise from medial frontal cortices³⁰. Recent results from intracranial EEG suggest that the alpha rhythm is generated by anterior ("higher-order") cortices and then travels posteriorly in a wave-like fashion, driving thalamic alpha-rhythm as well¹. With this background in mind, one might therefore hypothesize that alpha-power shifts might reflect dysfunction of a large-scale cortico-thalamic network that includes frontal cortex, and that disruption of this circuitry might be the common final pathway that links disparate clinical syndromes. This hypothesis could be tested with concurrent EEG-fMRI data, or by correlating EEG data with MRI-based cortex morphometry. Whether alphapower shifts are indeed causally involved in seizure liability could be further assessed in longitudinal studies: our results would predict that the alpha rhythm should shift back to normal frequency and configuration after treatment initiation, and that this effect might depend on the degree of underlying structural compromise.

Limitations of this study include its heterogenous in- and outpatient sample, and its reliance on seizure selfreports, which probably underestimate seizure occurrence. Barring invasive long-term recordings³¹, there is currently no other reliable approach to assess the ground truth of seizure frequency in any single patient. Scalp video-telemetry, particularly at home, might offer a solution, but seizure rates in this context will likely depend on a number of circumstantial factors, e.g. timing and tempo of AED weaning, and recording length. On the other hand, we note that we found a direct correlation between seizure frequency and alpha-power shifts (see supplemental materials). This indicates that, despite the shortcomings of seizure self-reports, our approach was sensitive enough to capture meaningful (continuous) variability between individual seizure load and alpha-rhythm abnormalities. Another concern is that our study had less power to detect interactions between syndrome type and levels of seizure control, given the low number of patients in each subgroup. However, we note effects for the different subgroup contrasts were large compared to the interaction contrast, which had an exceedingly low effect size ($\eta^2 = 0.006$). It seems therefore unlikely that we missed an interaction in the present data set. Finally, excessive daytime sleepiness is a well-known phenomenon in patients with epilepsy³², and sleep homeostasis might be particularly disrupted in drug-resistant patients³³. Since we did not assess sleepiness explicitly, it cannot be definitively ruled out, and we think it should be recorded systematically in future studies (e.g. with patient questionnaires). Even so, given that our analyses ruled out circadian differences in EEG recordings, and the fact that experienced neurophysiologists selected the analyzed EEG segments, it seems highly unlikely that sleepiness played a major role in our data.

In sum, we show that the resting-state human alpha rhythm is slower and extends frontally in patients with epilepsy, a phenomenon that we were able to link to seizure control across clinical syndrome boundaries. While the pathophysiology of such resting-state alterations remains to be explored³⁴, we hypothesize that this effect could be commensurate with the degree of cortico-thalamic dysfunction. This type of analysis could therefore provide a gateway to understand the pathophysiology of epilepsy or to develop epilepsy biomarkers that does not depend on the recording of epileptiform signals.

Acknowledgments

We are indebted to our patients for participating in our research. We thank Dr Lina Nashef, MD, for referring patients, Ms Ana Ribeiro for recording outpatient EEGs, and Dr Antonio Valentín, MD, for help with EEG data review. This study represents independent research supported by a Medical Research Council (MRC) Programme grant number

MR/K013998/1. MPR is supported in part by the National Institute for Health Research (NIHR) Biomedical Research Centre at the South London and Maudsley Hospital NHS Foundation Trust and King's College London; by the Engineering and Physical Sciences Research Council (EPSRC) Centre in Predictive Modelling in Health Care grant number EP/N014391/1; and by the MRC Centre for Neurodevelopmental Disorders grant number MR/N026063/1. EA is funded by the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 75088.

Author's Contributions

A.P. and E.A. conceived of the study. E. A. participated in collection of clinical data, wrote all software code, performed all data analyses, interpreted results and drafted/revised the manuscript, tables and figures. A.P. collected and curated all clinical and EEG data, drafted/reviewed the manuscript. C.T. and S.N.Y. participated in data analysis and reviewed the manuscript. F.B. and R.D.C.E helped with visual EEG data analysis and selection. M.P.R. supervised the study and its design, interpreted data, and revised manuscript and figures.

Potential conflicts of interest

Nothing to report

REFERENCES

- 1. Halgren M, Devinsky O, Doyle WK, et al. The Generation and Propagation of the Human Alpha Rhythm. bioRxiv 2017;
- 2. Smith SJM. EEG in neurological conditions other than epilepsy: When does it help, what does it add? Neurol. Pract. 2005;76(2):8–13.
- 3. Gibbs FA, Gibbs EL, Lennox WG. Electroencephalographic classification of epileptic patients and control subjects. Arch. Neurol. Psychiatry 1943;50(2):111.
- 4. Stoller A. Slowing of the Alpha-Rhythm of the Electro-Encephalogram and its Association with Mental Deterioration and Epilepsy. Br. J. Psychiatry 1949;95(401):972–984.
- 5. Pyrzowski J, Siemiński M, Sarnowska A, et al. Interval analysis of interictal EEG: pathology of the alpha rhythm in focal epilepsy. Sci. Rep. 2015;5:16230.
- 6. Miyauchi T, Endo K, Yamaguchi T, Hagimoto H. Computerized analysis of EEG background activity in epileptic patients. Epilepsia 1991:32(6):870–81.
- 7. Clemens B, Szigeti G, Barta Z. EEG frequency profiles of idiopathic generalised epilepsy syndromes. Epilepsy Res. 2000;42(2–3):105–115.
- 8. Clemens B. Pathological theta oscillations in idiopathic generalised epilepsy. Clin. Neurophysiol. 2004;115(6):1436–1441.
- 9. Doose H, Castiglione E, Waltz S. Parental generalized EEG alpha activity predisposes to spike wave discharges in offspring. Hum. Genet. 1995;96(6):695–704.
- 10. Santiago-Rodríguez E, Harmony T, Cárdenas-Morales L, et al. Analysis of background EEG activity in patients with juvenile myoclonic epilepsy. Seizure 2008;17(5):437–445.
- 11. Richardson MP. Large scale brain models of epilepsy: dynamics meets connectomics. J. Neurol. Neurosurg. Psychiatry 2012;83(12):1238–1248.
- 12. Chowdhury FA, Woldman W, FitzGerald THB, et al. Revealing a brain network endophenotype in families with idiopathic generalised epilepsy. PLoS One 2014;9(10):e110136.
- 13. Petkov G, Goodfellow M, Richardson MP, Terry JR. A critical role for network structure in seizure onset: a computational modeling approach. Front. Neurol. 2014;5:261.
- 14. Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: Position paper of the ILAE

- Commission for Classification and Terminology. Epilepsia 2017;58(4):512–521.
- 15. Fisher RS, Cross JH, D'Souza C, et al. Instruction manual for ILAE 2017 operational classification of seizure types. Epilepsia 2017;1–12.
- 16. Chowdhury FA, Elwes RDC, Koutroumanidis M, et al. Impaired cognitive function in idiopathic generalized epilepsy and unaffected family members: An epilepsy endophenotype. Epilepsia 2014;55(6):835–40.
- 17. Pawley AD, Chowdhury FA, Tangwiriyasakul C, et al. Cortical excitability correlates with seizure control and epilepsy duration in chronic epilepsy. Ann. Clin. Transl. Neurol. 2017;4(2):87–97.
- 18. Oostenveld R, Fries P, Maris E, Schoffelen JM. FieldTrip: Open source software for advanced analysis of MEG, EEG, and invasive electrophysiological data. Comput. Intell. Neurosci. 2011;2011
- 19. Whitham EM, Pope KJ, Fitzgibbon SP, et al. Scalp electrical recording during paralysis: Quantitative evidence that EEG frequencies above 20 Hz are contaminated by EMG. Clin. Neurophysiol. 2007;118(8):1877–1888.
- 20. Shackman AJ, McMenamin BW, Maxwell JS, et al. Identifying robust and sensitive frequency bands for interrogating neural oscillations. Neuroimage 2010;51(4):1319–1333.
- 21. Chiang AKI, Rennie CJ, Robinson PA, et al. Age trends and sex differences of alpha rhythms including split alpha peaks. Clin. Neurophysiol. 2011;122(8):1505–1517.
- 22. Clemens B, Ménes A, Piros P, et al. Quantitative EEG effects of carbamazepine, oxcarbazepine, valproate, lamotrigine, and possible clinical relevance of the findings. Epilepsy Res. 2006;70(2–3):190–199.
- 23. Kilner JM, Friston KJ. Topological inference for EEG and MEG. Ann. Appl. Stat. 2010;4(3):1272–1290.
- Winkler AM, Ridgway GR, Webster MA, et al. Permutation inference for the general linear model. Neuroimage 2014;92:381–97.
- Hentschke H, Stüttgen MC. Computation of measures of effect size for neuroscience data sets. Eur. J. Neurosci.
 2011;34(12):1887–1894.
- 26. James G, Witten D, Hastie T, Tibshirani R. An Introduction to Statistical Learning. New York, NY: Springer New York; 2013.
- 27. Morel P. Gramm: grammar of graphics plotting in Matlab. J. Open Source Softw. 2018;3(23):568.
- 28. Whelan CD, Altmann A, Botía JA, et al. Structural brain abnormalities in the common epilepsies assessed in a worldwide ENIGMA study. Brain 2018;141(2):391–408.
- 29. O'Muircheartaigh J, Richardson MP. Epilepsy and the frontal lobes. Cortex 2012;48(2):144–155.

- 30. Cohen MX, Van Gaal S. Dynamic interactions between large-scale brain networks predict behavioral adaptation after perceptual errors. Cereb. Cortex 2013;23(5):1061–1072.
- 31. Baud MO, Kleen JK, Mirro EA, et al. Multi-day rhythms modulate seizure risk in epilepsy. Nat. Commun. 2018;9(1):88.
- 32. Giorelli AS, Passos P, Carnaval T, Gomes M da M. Excessive Daytime Sleepiness and Epilepsy: A Systematic Review. Epilepsy Res. Treat. 2013;2013:1–9.
- 33. Boly M, Jones B, Findlay G, et al. Altered sleep homeostasis correlates with cognitive impairment in patients with focal epilepsy. Brain 2017;140(4):1026–1040.
- 34. Schaul N. Pathogenesis and significance of abnormal nonepileptiform rhythms in the EEG. J. Clin. Neurophysiol. 1990;7(2):229–48.

Figure 1. Alpha power is shifted towards lower frequencies in patients with poor seizure control across clinical

syndromes. The three plots in the upper row (A-C) compare the following pairs of power spectra (from left to right):

FIGURE LEGENDS

patients versus healthy subjects, patients with poor-versus good seizure control, and patients with focal versus idiopathic generalized epilepsy. Lines indicate group averages and shaded areas 95% confidence intervals (CI). Tick marks and black lines above the x-axis show frequencies at which power spectra diverge: a shift towards lower alpha frequencies can be appreciated for the whole patient cohort, for poor seizure control, and for focal epilepsy subgroups. Plots D and E show the statistical assessment of this observations in terms of the (log-transformed) alpha-power shift, i.e. the ratio of average low- to average high alpha-power. Higher values indicate more low-alpha power. Dots and error bars represent means ± 95% CI. P-values are derived from pair-wise contrasts of two analyses of covariance (see Methods for details). There was a significant difference between healthy subjects and patients, which was driven by poor seizure control patients (p<.001, panel D). The power spectrum of focal epilepsy patients was more shifted than the power spectrum of idiopathic generalized epilepsy patients (p=.007, Panel E, horizontal line). However, there was no syndrome-by-seizure control interaction: alpha power in poor seizure control patients was always more shifted than alpha power in GSC patients (p=.001), and this occurred in equal measure in both syndrome categories (Panel E, vertical line). Figure 2. Alpha-power shifts are topographically extended, indicating a forward spread of low-alpha power. This figure shows topographical maps for three pair-wise comparisons: panel (A), healthy subjects versus all epilepsy patients, panel (B), good-seizure control versus poor-seizure control patients, and panel (C), idiopathic generalized epilepsy versus focal epilepsy patients. The first two columns on the left show raw data: positive values (red) indicate a shift of EEG power towards the low-alpha band, negative (blue) values a shift towards the high alpha band. The third and fourth column show statistical maps, i.e. p-values and effect sizes, respectively. Maps of family-wise error (FWE) corrected p-values were derived using permutation tests. White areas did not reach the significance threshold. The last column shows effect size maps (Hedges' g), where g = 0.2 represents a weak, and g = 1.3 a very large effect. Note that all patients present significant shifts of alpha power compared to healthy controls over the entire scalp (panel A), with large effects occipitally, and that this effect is particularly pronounced in poor seizure control patients: very large effects are seen here over bilateral and midline frontal regions (panel B). Finally, t focal epilepsy patients had more frontal alpha-power shift, i.e. more low-alpha power, over frontal regions compared to idiopathic generalized epilepsy patients, (panel C).

TABLES

Table 1. Demographic and clinical characteristics in healthy subjects (HS), epilepsy patients with good seizure control (GSC), and epilepsy patients with poor seizure control (PSC)

Disease characteristics		HS (n = 39)	GSC (n = 25)	PSC (n = 38)	Statistic	p
Disease characteristies Disease duration, y - $16 \pm 10 (1-42)$ $17 \pm 15 (2-58)$ U = 424.5 .482 FE syndrome, n(%) - $10 (40)$ $27 (71)$ $\chi^2 (1, 63) = 6.00$.014 FE left lateralized, n(%) - $5 (20)^4$ $14 (37)^4$ Fisher's exact test .175 FE right lateralized, n(%) 3 (12) $12 (32)$ Fisher's exact test .233 AS, n(%) - 4 (16) 4 (11) Fisher's exact test .233 AS, n(%) - 1 (4) 24 (62) Fisher's exact test .512 FEG characteristics 1 (4) 24 (62) Fisher's exact test .592 FEG characteristics <td>Female sex, n (%)</td> <td>19 (49)</td> <td>15 (60)</td> <td>19 (50)</td> <td>$\chi^2(2, 102) = 0.87$</td> <td>.647</td>	Female sex, n (%)	19 (49)	15 (60)	19 (50)	$\chi^2(2, 102) = 0.87$.647
Disease duration, y - $16\pm10 (1-42)$ $17\pm15 (2-58)$ $U=424.5$ $.482$ FE syndrome, n (%) - $10 (40)$ $27 (71)$ $2^2 (1,63) = 6.00$.014 FE left lateralized, n (%) - $5 (20)^*$ $14 (37)^*$ Fisher's exact test .175 FE right lateralized, n (%) - $4 (16)$ $12 (32)$ Fisher's exact test .125 GTCS, n (%) - $4 (16)$ $12 (32)$ Fisher's exact test .233 AS, n (%) - $4 (16)$ $4 (11)$ $16 (10)$ $17 (10)$	Age, y	30 ± 9 (18 - 53)	33 ± 12 (20 - 77)	38 ± 14 (20 - 68)	H = 4.62	.099
FE syndrome, n (%) - 10 (40) 27 (71) χ^2 (1, 63) = 6.00 .014 FE left lateralized, n (%) - 5 (20)* 14 (37)* Fisher's exact test .175 FE right lateralized, n (%) - 3 (12) 12 (32) Fisher's exact test .233 GTCS, n (%) - 4 (16) 4 (11) Fisher's exact test .394 F1AS, n (%) - 1 (4) 24 (62) Fisher's exact test .304 F1AS, n (%) - 0 (0) 2 (5) Fisher's exact test .304 F1AS, n (%) - 1 (4) 3 (8) Fisher's exact test .513 EEG characteristics 3 4 (16) 15 (39) Fisher's exact test .995 F0cal slowing, n (%) - 4 (16) 15 (39) Fisher's exact test .055 GSWD, n (%) - 4 (19) 15 (39) Fisher's exact test .055 GSWD, n (%) - 4 (19) 15 (39) Fisher's exact test .055 MRI characteristics** 1	Disease characteristics					
FE left lateralized, n (%) 5 (20)* 14 (37)* Fisher's exact test 1.75 FE right lateralized, n (%) 3 (12) 12 (32) Fisher's exact test 1.23 GTCS, n (%) 4 (16) 12 (32) Fisher's exact test 2.33 AS, n (%) 4 (16) 4 (11) Fisher's exact test 3.94 FIAS, n (%) 0 (0) 2 (5) Fisher's exact test 3.94 FEC characteristics 80 Fisher's exact test 9.95 EEG characteristics 995 1 (4) 3 (8) Fisher's exact test 9.95 Focal slowing, n (%) 1 (4) 3 (8) Fisher's exact test 9.95 GSWD, n (%) 2 (4(16) 15 (39) Fisher's exact test 9.95 GSWD, n (%) 3 (14) 15 (39) Fisher's exact test 0.05 MRI characteristics 1 10 (26) Fisher's exact test 0.05 MRI characteristics 1 10 (3) 17 (50) Fisher's exact test 0.05 MRI characteristics 1 2 (8) 6	Disease duration, y	-	$16 \pm 10 (1 - 42)$	$17 \pm 15 (2 - 58)$	U = 424.5	.482
FE right lateralized, n (%) 3 (12) 12 (32) Fisher's exact test 1.25 GTCS, n (%) 4 (16) 12 (32) Fisher's exact test 2.33 AS, n (%) 4 (16) 4 (11) Fisher's exact test 3.94 FIAS, n (%) 1 (4) 24 (62) Fisher's exact test 5.13 EEG characteristis Background slowing, n (%) 1 (4) 3 (8) Fisher's exact test 9.95 Focal slowing, n (%) 4 (16) 15 (39) Fisher's exact test 0.55 GSWD, n (%) 4 (19) 15 (39) Fisher's exact test 0.05 GSWD, n (%) 4 (19) 15 (39) Fisher's exact test 0.05 MRI characteristics Lesion, n (%) 3 (14) 17 (50) Fisher's exact test 0.05 MTS, n (%) 2 (8) 6 (16) Fisher's exact test 0.05 Medicator AED, n 1 (1-3)^5 2 (2-3) U = 37, 9 11 AED drug load, a, u - 1.4 ± 0.9 (0.4 + 4.3) 1.5 ± 0.	FE syndrome, n (%)	-	10 (40)	27 (71)	$\chi^2(1, 63) = 6.00$.014
GTCS, n (%) - 4 (16) 12 (32) Fisher's exact test 2.33 AS, n (%) - 4 (16) 4 (11) Fisher's exact test 3.394 FIAS, n (%) - 1 (14) 24 (62) Fisher's exact test 4.00 FAS, n (%) - 0 (0) 2 (5) Fisher's exact test 5.13 FEG characteristics 3ackground slowing, n (%) - 1 (4) 3 (8) Fisher's exact test 5.13 FEG characteristics Focal slowing, n (%) - 4 (16) 15 (39) Fisher's exact test 5.05 GSWD, n (%) - 5 (25) 10 (26) Fisher's exact test 5.63 MRI characteristics' Lesion, n (%) - 3 (14) 17 (50) Fisher's exact test 5.00 MRI characteristics' AED, n - 2 (8) 6 (16) Fisher's exact test 5.46 Medication AED, n - 1 (1 - 3)! 2 (2 - 3) U = 375.9 1.15 AED drug load, a. u 1.4 ± 0.9 (0.4 - 4.3) 1.5 ± 0.8 (0.2 - 4.0) U = 417.0 4.18 Patients on LTG, n (%) - 10 (40) 12 (32) Fisher's exact test 8.02 LTG dosage, mg - 350 ± 91 (200 - 450) 242 ± 120 (50 - 400) t (20) = 2.3 5.03 Patients on LEV, n (%) - 7 (28) 11 (29) Fisher's exact test 5.995 LEV dosage, mg - 1500 ± 595 (750 - 2500) 1550 ± 934 (300 - 3000) t (16) = -0.13 5.992	FE left lateralized, n (%)	-	5 (20)*	14 (37)*	Fisher's exact test	.175
AS, n (%) - 4 (16) 4 (11) Fisher's exact test 3,394 FIAS, n (%) - 1 (4) 24 (62) Fisher's exact test <00 FAS, n (%) - 0 (00) 2 (5) Fisher's exact test <00 FAS, n (%) - 0 (00) 2 (5) Fisher's exact test <00 FISHER'S exact te	FE right lateralized, n (%)		3 (12)	12 (32)	Fisher's exact test	.129
FIAS, n (%) - 1 (4) 24 (62) Fisher's exact test <00 cm. Fight (a) = 1 (4) 24 (62) Fisher's exact test <00 cm. Fight (b) = 1 (4) 24 (62) Fisher's exact test <00 cm. Fis	GTCS, n (%)	-	4 (16)	12 (32)	Fisher's exact test	.233
FAS, n (%) - 0 (0) 2 (5) Fisher's exact test .513 EEG characteristics 3ackground slowing, n (%) - 1 (4) 3 (8) Fisher's exact test .995 Focal slowing, n (%) - 4 (16) 15 (39) Fisher's exact test .055 GSWD, n (%) - 5 (25) 10 (26) Fisher's exact test .062 IED, n (%) - 4 (19) 15 (39) Fisher's exact test .002 MRI characteristics Lesion, n (%) - 3 (14) 17 (50) Fisher's exact test .002 MTS, n (%) - 2 (8) 6 (16) Fisher's exact test .046 Medication AED, n - 1 (1 - 3) 2 (2 - 3) U = 375.9 .115 AED drug load, a. u 1.4 ± 0.9 (0.4 - 4.3) 1.5 ± 0.8 (0.2 - 4.0) U = 417.0 .418 Patients on LTG, n (%) - 10 (40) 12 (32) Fisher's exact test .802 LTG dosage, mg - 350 ± 91 (200 - 450) 242 ± 120 (50 - 400) t(20) = 2.3 0.30 Patients on LEV, n (%) - 7 (28) 11 (29) Fisher's exact test .995 LEV dosage, mg - 1500 ± 595 (750 - 2500) 1550 ± 934 (300 - 3000) t(16) = -0.13 .992	AS, n (%) -		4 (16)	4 (11)	Fisher's exact test	.394
EEG characteristics 3ackground slowing, n (%) -	FIAS, n (%)	-	1 (4)	24 (62)	Fisher's exact test	<.00
Background slowing, n (%) - 1 (4) 3 (8) Fisher's exact test .995 Focal slowing, n (%) - 4 (16) 15 (39) Fisher's exact test .055 GSWD, n (%) - 5 (25) 10 (26) Fisher's exact test .002 MRI characteristics* Lesion, n (%) - 3 (14) 17 (50) Fisher's exact test .005 MTS, n (%) - 2 (8) 6 (16) Fisher's exact test .246 Medication AED, n - 1 (1 - 3)\frac{1}{2} 2 (2 - 3) U = 375.9 .115 AED drug load, a. u. - 1 .4 ± 0.9 (0.4 - 4.3) 1 .5 ± 0.8 (0.2 - 4.0) U = 417.0 .418 Patients on LTG, n (%) - 10 (40) 12 (32) Fisher's exact test .802 LTG dosage, mg - 350 ± 91 (200 - 450) 242 ± 120 (50 - 400) t(20) = 2.3\frac{1}{2} .030 Patients on LEV, n (%) - 7 (28) 11 (29) Fisher's exact test .995 LEV dosage, mg - 1500 ± 595 (750 - 2500) 1550 ± 934 (300 - 3000) t(16) = -0.13	FAS, n (%)	-	0 (0)	2 (5)	Fisher's exact test	.513
Focal slowing, n (%) - 4 (16) 15 (39) Fisher's exact test .055 GSWD, n (%) - 5 (25) 10 (26) Fisher's exact test .764 IED, n (%) - 4 (19) 15 (39) Fisher's exact test .002 MRI characteristics' Lesion, n (%) - 3 (14) 17 (50) Fisher's exact test .005 MTS, n (%) - 2 (8) 6 (16) Fisher's exact test .246 Medication AED, n - 1 (1 - 3) [¶] 2 (2 - 3) U = 375.9 .119 AED drug load, a. u 1.4 ± 0.9 (0.4 - 4.3) 1.5 ± 0.8 (0.2 - 4.0) U = 417.0 .418 Patients on LTG, n (%) - 10 (40) 12 (32) Fisher's exact test .802 LTG dosage, n g - 350 ± 91 (200 - 450) 242 ± 120 (50 - 400) t(20) = 2.3 ± .036 Patients on LEV, n (%) - 7 (28) 11 (29) Fisher's exact test .999 LEV dosage, n g - 1500 ± 595 (750 - 2500) 1550 ± 934 (300 - 3000) t(16) = -0.13 .902	EEG characteristics					
GSWD, n (%) - 5 (25) 10 (26) Fisher's exact test .764 IED, n (%) - 4 (19) 15 (39) Fisher's exact test .002 MRI characteristics* Lesion, n (%) - 3 (14) 17 (50) Fisher's exact test .005 MTS, n (%) - 2 (8) 6 (16) Fisher's exact test .246 Medication AED, n - 1 (1 - 3)\frac{1}{1} 2 (2 - 3) U = 375.9 .115 AED drug load, a. u 1.4 \pm 0.9 (0.4 - 4.3) 1.5 \pm 0.8 (0.2 - 4.0) U = 417.0 .418 Patients on LTG, n (%) - 10 (40) 12 (32) Fisher's exact test .802 LTG dosage, mg - 350 \pm 91 (200 - 450) 242 \pm 120 (50 - 400) t(20) = 2.3\pm 0.300 Patients on LEV, n (%) - 7 (28) 11 (29) Fisher's exact test .999 LEV dosage, mg - 1500 \pm 595 (750 - 2500) 1550 \pm 934 (300 - 3000) t(16) = -0.13 .902	Background slowing, n (%)	-	1 (4)	3 (8)	Fisher's exact test	.999
IED, n (%) - 4 (19) 15 (39) Fisher's exact test .002 MRI characteristics* Lesion, n (%) - 3 (14) 17 (50) Fisher's exact test .005 MTS, n (%) - 2 (8) 6 (16) Fisher's exact test .246 Medication AED, n - 1 (1-3)* 2 (2-3) U = 375.9 .119 AED drug load, a. u 1.4 ± 0.9 (0.4 - 4.3) 1.5 ± 0.8 (0.2 - 4.0) U = 417.0 .418 Patients on LTG, n (%) - 10 (40) 12 (32) Fisher's exact test .802 LTG dosage, mg - 350 ± 91 (200 - 450) 242 ± 120 (50 - 400) t(20) = 2.3‡ .030 Patients on LEV, n (%) - 7 (28) 11 (29) Fisher's exact test .999 LEV dosage, mg - 1500 ± 595 (750 - 2500) 1550 ± 934 (300 - 3000) t(16) = -0.13 .902	Focal slowing, n (%)	-	4 (16)	15 (39)	Fisher's exact test	.055
MRI characteristics* Lesion, n (%) - 3 (14) 17 (50) Fisher's exact test .005 MTS, n (%) - 2 (8) 6 (16) Fisher's exact test .246 Medication AED, n - 1 (1 - 3)¶ 2 (2 - 3) U = 375.9 .119 AED drug load, a. u. - 1.4 ± 0.9 (0.4 - 4.3) 1.5 ± 0.8 (0.2 - 4.0) U = 417.0 .418 Patients on LTG, n (%) - 10 (40) 12 (32) Fisher's exact test .802 LTG dosage, mg - 350 ± 91 (200 - 450) 242 ± 120 (50 - 400) t(20) = 2.3‡ .030 Patients on LEV, n (%) - 7 (28) 11 (29) Fisher's exact test .999 LEV dosage, mg - 1500 ± 595 (750 - 2500) 1550 ± 934 (300 - 3000) t(16) = -0.13 .902	GSWD, n (%)	-	5 (25)	10 (26)	Fisher's exact test	.764
Lesion, n (%) - 3 (14) 17 (50) Fisher's exact test .005 MTS, n (%) - 2 (8) 6 (16) Fisher's exact test .246 Medication AED, n - $1 (1-3)^{\P}$ 2 (2-3) U = 375.9 .119 AED drug load, a. u. - $1.4 \pm 0.9 (0.4 - 4.3)$ $1.5 \pm 0.8 (0.2 - 4.0)$ U = 417.0 .418 Patients on LTG, n (%) - 10 (40) 12 (32) Fisher's exact test .802 LTG dosage, mg - $350 \pm 91 (200 - 450)$ $242 \pm 120 (50 - 400)$ $t(20) = 2.3^{\ddagger}$.030 Patients on LEV, n (%) - 7 (28) 11 (29) Fisher's exact test .999 LEV dosage, mg - $1500 \pm 595 (750 - 2500)$ $1550 \pm 934 (300 - 3000)$ $t(16) = -0.13$.902	IED, n (%)	-	4 (19)	15 (39)	Fisher's exact test	.002
MTS, n (%) - 2 (8) 6 (16) Fisher's exact test .246 Medication AED, n - $1 (1-3)^{4}$ 2 (2-3) U = 375.9 .119 AED drug load, a. u. - $1.4 \pm 0.9 (0.4 - 4.3)$ $1.5 \pm 0.8 (0.2 - 4.0)$ U = 417.0 .418 Patients on LTG, n (%) - 10 (40) 12 (32) Fisher's exact test .802 LTG dosage, mg - $350 \pm 91 (200 - 450)$ $242 \pm 120 (50 - 400)$ t(20) = 2.3^{\ddagger} .030 Patients on LEV, n (%) - 7 (28) 11 (29) Fisher's exact test .999 LEV dosage, mg - $1500 \pm 595 (750 - 2500)$ $1550 \pm 934 (300 - 3000)$ t(16) = -0.13 .902	MRI characteristics†					
Medication AED, n - $1 (1-3)^{\P}$ $2 (2-3)$ U = 375.9 .119 AED drug load, a. u. - $1.4 \pm 0.9 (0.4 - 4.3)$ $1.5 \pm 0.8 (0.2 - 4.0)$ U = 417.0 .418 Patients on LTG, n (%) - 10 (40) 12 (32) Fisher's exact test .802 LTG dosage, mg - $350 \pm 91 (200 - 450)$ $242 \pm 120 (50 - 400)$ t(20) = 2.3^{\ddagger} .030 Patients on LEV, n (%) - $7 (28)$ 11 (29) Fisher's exact test .999 LEV dosage, mg - $1500 \pm 595 (750 - 2500)$ $1550 \pm 934 (300 - 3000)$ t(16) = -0.13 .902	Lesion, n (%)	-	3 (14)	17 (50)	Fisher's exact test	.005
AED, n - $1(1-3)^{\P}$ 2 (2 - 3) U = 375.9 .119 AED drug load, a. u $1.4 \pm 0.9 (0.4 - 4.3)$ $1.5 \pm 0.8 (0.2 - 4.0)$ U = 417.0 .418 Patients on LTG, n (%) - $10 (40)$ $12 (32)$ Fisher's exact test .802 LTG dosage, mg - $350 \pm 91 (200 - 450)$ $242 \pm 120 (50 - 400)$ $t(20) = 2.3^{\ddagger}$.030 Patients on LEV, n (%) - $7 (28)$ $11 (29)$ Fisher's exact test .999 LEV dosage, mg - $1500 \pm 595 (750 - 2500)$ $1550 \pm 934 (300 - 3000)$ $t(16) = -0.13$.902	MTS, n (%)	-	2 (8)	6 (16)	Fisher's exact test	.246
AED drug load, a. u $1.4 \pm 0.9 (0.4 - 4.3)$ $1.5 \pm 0.8 (0.2 - 4.0)$ $U = 417.0$.418 Patients on LTG, n (%) - $10 (40)$ $12 (32)$ Fisher's exact test .802 LTG dosage, mg - $350 \pm 91 (200 - 450)$ $242 \pm 120 (50 - 400)$ $t(20) = 2.3^{\ddagger}$.030 Patients on LEV, n (%) - $7 (28)$ $11 (29)$ Fisher's exact test .999 LEV dosage, mg - $1500 \pm 595 (750 - 2500)$ $1550 \pm 934 (300 - 3000)$ $t(16) = -0.13$.902	Medication					
Patients on LTG, n (%) - 10 (40) 12 (32) Fisher's exact test .802 LTG dosage, mg - $350 \pm 91 (200 - 450)$ 242 $\pm 120 (50 - 400)$ t(20) = 2.3^{\ddagger} .030 Patients on LEV, n (%) - 7 (28) 11 (29) Fisher's exact test .999 LEV dosage, mg - $1500 \pm 595 (750 - 2500)$ 1550 $\pm 934 (300 - 3000)$ t(16) = -0.13 .902	AED, n	-	1 (1 - 3)¶	2 (2 - 3)	U = 375.9	.119
LTG dosage, mg - $350 \pm 91 (200 - 450)$ $242 \pm 120 (50 - 400)$ $t(20) = 2.3^{\ddagger}$.030 Patients on LEV, n (%) - $7 (28)$ 11 (29) Fisher's exact test .999 LEV dosage, mg - $1500 \pm 595 (750 - 2500)$ $1550 \pm 934 (300 - 3000)$ $t(16) = -0.13$.902	AED drug load, a. u.	-	$1.4 \pm 0.9 \ (0.4 - 4.3)$	$1.5 \pm 0.8 (0.2 - 4.0)$	U = 417.0	.418
Patients on LEV, n (%) - $7(28)$	Patients on LTG, n (%)	-	10 (40)	12 (32)	Fisher's exact test	.802
LEV dosage, mg - $1500 \pm 595 (750 - 2500)$ $1550 \pm 934 (300 - 3000)$ $t(16) = -0.13$.902	LTG dosage, mg	-	$350 \pm 91 \ (200 - 450)$	$242 \pm 120 (50 - 400)$	$t(20) = 2.3^{\ddagger}$.030
	Patients on LEV, n (%)	-	7 (28)	11 (29)	Fisher's exact test	.999
Patients on VPA, n (%) - 8 (32) 10 (26) Fisher's exact test .789	LEV dosage, mg	-	$1500 \pm 595 (750 - 2500)$	$1550 \pm 934 (300 - 3000)$	t(16) = -0.13	.902
	Patients on VPA, n (%)	-	8 (32)	10 (26)	Fisher's exact test	.789

PAGE 21


VPA dosage, mg	-	$838 \pm 307 (300 - 1200)$	$1000 \pm 531 (300 - 2000)$	t(16) = -0.77	.455
Patients on CBZ, n (%)	-	6 (24)	10 (26)	Fisher's exact test	.999
CBZ dosage, mg	-	833 ± 497 (400 - 1400)	$690 \pm 277 (200 - 1000)$	U = 35.0	.618
Others, n	-	2 ETX, 1 LAC, 1 TGB, 1 TPM, 1 ZNS	2 LAC, 1 OXC, 3 PHT, 1 TGB, 6 TPM, 2 ZNS	-	-


Abbreviations: AED, antiepileptic drugs, a. u., arbitrary units; AS, absence seizures, F/M, female/male; FAS, focal aware seizures; FE, focal epilepsy; FIAS, focal impaired awareness seizures; GTCS, generalized tonic-clonic seizures; GSWD, generalized spike-wave discharges; H, Kruskal-Wallis tests; IED, interictal epileptiform discharges; IGE, idiopathic generalized epilepsy; MTS, mesial temporal lobe sclerosis; MRI, magnetic resonance imaging; n, number; t-test (degrees of freedom); U, Mann-Whitney-U-test; χ^2 , Chi-square test (degrees of freedom, sample size); y, years. AED names: CBZ, carbamazepine; ETX, ethosuximide; LAC, lacosamide; LEV, levetiracetam; LTG, lamotrigine; OXC, oxcarbazepine; PHT, phenytoin; TGB, tiagabine; TPM, topiramate; VPA, valproic acid; ZNS, zonisamide. Notes: numbers are given as mean \pm SD (range), unless stated otherwise, and all p-values are two-tailed. (*) Lateralization was unclear for 2 GSC and 1 PSC patient with FE. (†) MRI reports were not available in 1 patient with good, and 4 patients with poor seizure control. (‡) T-tests where used if data met normality assumptions, U-tests otherwise. (¶) Median (range).

Table 2. Statistical results for alpha-power shift topographies

Factors	Covariates	Contrast	Peak statistic (df)	p(FWE)*	Effect size g [95% CI] [†]	Nearest electrode
Group (healthy subjects, GSC patients, PSC patients)	Age, Gender	PAT > HS	t(97) = 4.52	<.001	1.03 [0.65, 1.47]	Т6
Seizure control (GSC, PSC)	Age, Gender, AED load	PSC > GSC	t(56) = 4.31	< .001	1.28 [0.86, 1.80]	C3
Syndrome (IGE, FE)	Age, Gender, AED load	IGE < FE	t(56) = 2.72	.031	-1.15 [-0.65, -1.81	01

<u>Abbreviations:</u> AED, antiepileptic drugs; CI, confidence interval; df, degrees of freedom; FE, focal epilepsy; GSC, good seizure control; HS, healthy subjects; IGE, idiopathic generalized epilepsies; n. s., not significant; PAT, all patients; PSC, poor seizure control. <u>Notes:</u> Electrode names follow the standard 10-20 system. (*) p-values have been family-wise error (FWE) corrected using Gaussian random fields. (†) Effect size measure based on mean differences divided by the pooled and weighted standard deviation. Interpretation: 0.2 = small, 0.5 = medium; 0.8 = large, 1.2 = very large effect. Confidence intervals were derived from 5000 bootstrap samples





Supplemental Materials

Content

This document describes supplementary analyses to Abela, Pawley et al., "Slower alpha rhythm associates with poorer seizure control in epilepsy". The order of analyses is as follows:

Analysis 1	Re-analysis using individual alpha frequencies (IAF) instead of alpha-power shift.
Analysis 2	Test of reproducibility using a second segment of EEG data.
Analysis 3	Assessment of two alternative seizure-control definitions, i.e.
	(a) Good seizure control: no seizures versus poor seizure control: any seizures,
	(b) Good seizure control: below median of seizure frequency versus poor seizure control: above median of seizure frequency.
Analysis 4	Correlation analysis using a continuous measure of seizure frequency
Analysis 5	Comparing EEG recording times across groups to assess potential circadian effects
Analysis 6	Additional control for anti-epileptic drug (AED) effects.
Analysis 7	Topographic analysis to rule out lesional effects on spatial alpha-power shifts

All statistical analyses were done in JASP (Version 0.8.6, https://jasp-stats.org/), if not noted otherwise. Links point to extended results on the Open Science Framework (www.osf.io).

Analysis 1: Re-analysis using individual alpha frequencies (IAF) instead of alpha-power shift.

Rationale and method

We sought to confirm that alpha-power shifts were indeed accompanied by a deceleration of the individual alpha frequency (IAF). Because we calculated the alpha-power shift as a ratio between fixed frequency bands, a significant shift could occur due to redistribution of power between bands, without actual slowing of the peak individual alpha rhythm. We thus found the IAF as the frequency of maximum power in the extended alpha-band (6-13Hz), and compared individual log-transformed IAF between patient groups, using the same ANCOVA model described in the main manuscript. Our hypothesis was that, as in the main analysis, IAF would differ between seizure-control groups, but that there would not be an interaction between syndrome type (focal versus generalised) and seizure control.

Results (Link: https://osf.io/739qr/)

ANCOVA - IAF (log)

Cases	Sum of Squares	df	Mean Square	F	p
Seizure control	0.037	1.000	0.037	7.283	0.009
Syndrome	0.016	1.000	0.016	3.052	0.086
Seizure control * Syndrome	2.352e -4	1.000	2.352e -4	0.046	0.831
Gender	0.005	1.000	0.005	1.067	0.306
Age	6.955e -5	1.000	6.955e -5	0.014	0.907
AED Load	0.001	1.000	0.001	0.285	0.596
Residual	0.286	56.000	0.005		

Note. Type III Sum of Squares

Post Hoc Comparisons - Seizure control

	•	Mean Difference	SE	t	p bonf	
GSC	PSC	0.053	0.020	2.699	0.009	

Post Hoc Comparisons - Syndrome

		Mean Difference	SE	t	p bonf
FE	IGE	-0.035	0.020	-1.747	0.086

Conclusion

This analysis confirms that the alpha rhythm is indeed slower between seizure control groups. In contrast to the main analysis, there is no difference between FE and IGE, supporting the idea that slower alpha rhythm in epilepsy is syndrome-independent.

Analysis 2: Test of reproducibility using a second segment of EEG data.

Rationale and method

We assessed whether results differed between data segments. We thus repeated alpha-power shift comparisons for the average power spectra on a second data segment, which was available in 57/63 patients (missing in six because of considerable artefacts throughout the recording: 2 IGE, each in the GSC and PSC group, and 4 FE, 1 in the GSC and 3 in the PSC group). We applied the same ANCOVA model described in the main text.

Results (Link: https://osf.io/739qr/)

ANCOVA - Alpha-power shift (log) second segment

Cases	Sum of Squares	df	Mean Square	F	p
Seizure control	1.702	1.000	1.702	9.903	0.003
Syndrome	0.947	1.000	0.947	5.508	0.023
Syndrome * Seizure control	0.277	1.000	0.277	1.609	0.210
Gender	0.351	1.000	0.351	2.044	0.159
Age	0.007	1.000	0.007	0.042	0.839
AED Load	0.602	1.000	0.602	3.503	0.067
Residual	8.596	50.000	0.172		

Note. Type III Sum of Squares

Post Hoc Comparisons - Seizure control

		Mean Difference	SE	t	Cohen's d	p bonf
GSC	PSC	-0.381	0.121	-3.147	-0.852	0.003
Note C	'ahan'a d da	as not correct for multiple cor	manigang			

Note. Cohen's d does not correct for multiple comparisons.

Post Hoc Comparisons - Syndrome

		Mean Difference	SE	t	Cohen's d	p bonf
FE	IGE	0.287	0.122	2.347	0.633	0.023

Note. Cohen's d does not correct for multiple comparisons.

Conclusion

This analysis confirms that alpha-power is shifted towards lower frequencies in a second data set from the same recording, and thus reproducible within one recording session.

Analysis 3: Assessment of two alternative seizure-control definitions

Rationale and method

Because we used a heuristic for dividing patients into seizure-control subgroups, there is a concern that group differences might be sensitive to the seizure frequency thresholds used. Also, patients that are completely seizure free might differ neurobiologically from those with only a few seizures. We therefore tested two alternative seizure control definitions: a zero-split (i.e. patients without any seizures versus all others) and a median-split (i.e. patients with seizure frequency below versus above the median). We applied the same ANCOVA model described in the main text.

Results (Link: https://osf.io/ch78y/)

ANCOVA - Alpha-power shift (log) / Zero-split

THE OTHER POWER SHITE (108) / Extra	SPILE					
Cases	Sum of Squares	df	Mean Square	F	p	η^2
Seizure control (zero split)	1.471	1.000	1.471	7.441	0.009	0.103
Syndrome	1.333	1.000	1.333	6.741	0.012	0.093
Seizure control (zero split) * Syndrome	0.121	1.000	0.121	0.610	0.438	0.008
Gender	0.015	1.000	0.015	0.074	0.787	0.001
Age	0.008	1.000	0.008	0.040	0.842	0.001
AED Load	0.258	1.000	0.258	1.307	0.258	0.018
Residual	11.072	56.000	0.198			

Note. Type III Sum of Squares

Post Hoc Comparisons - Seizure control (Zero split)

		Mean Difference	SE	t	p bonf
GSC	PSC	-0.339	0.124	-2.728	0.009

Post Hoc Comparisons - Syndrome

	_	Mean Difference	SE	t	p bonf
FE	IGE	0.325	0.125	2.596	0.012

(continued on next page)

ANCOVA - Alpha-power shift (log) / Median-split

Cases	Sum of Squares	df	Mean Square	F	р	η²
Seizure control (median split)	1.742	1.000	1.742	8.940	0.004	0.121
Syndrome	1.450	1.000	1.450	7.438	0.009	0.101
Seizure control (median split) * Syndrome	5.230e -4	1.000	5.230e -4	0.003	0.959	0.000
Gender	0.016	1.000	0.016	0.081	0.777	0.001
Age	0.037	1.000	0.037	0.189	0.665	0.003
AED Load	0.195	1.000	0.195	1.001	0.321	0.014
Residual	10.913	56.000	0.195			

Note. Type III Sum of Squares

Post Hoc Comparisons - Seizure control (Median split)

		Mean Difference	SE	t	p bonf
GSC	PSC	-0.356	0.119	-2.990	0.004

Post Hoc Comparisons - Syndrome

		Mean Difference	SE	t	p bonf	
FE	IGE	0.333	0.122	2.727	0.009	

Conclusion

Two alternative seizure-control definitions yield qualitatively similar results to the main analysis, indicating that findings are not sensitive to the choice of threshold.


Analysis 4: Correlation analysis using a continuous measure of seizure frequency

Rationale and method

All analyses above and in the main manuscript were based on dichotomisation of patient groups based on seizure frequency. While results are consistent across three different criteria, they do not reveal the full extent of the variability in the data. To gain further insight into the relationship between alpha-rhythm alterations and seizure control, we calculated Pearson's correlation between individual alpha-power shift and self-reported seizure frequency across the patient cohort, without dichotomisation, both using channel-averaged and topographically-resolved alpha-power shift values. Both measures were log-transformed before correlation. An offset of 1 was added to the seizure frequency values before taking the log to avoid zero values. The topographical analysis with the same permutation-based methods are described in the main manuscript.

Results (Link: https://osf.io/npdx9/)

Average alpha-power shift across all channels was positively correlated with individual seizure frequency: Person's correlation coefficient, r = 0.403, p < .001 (Figure, left panel). Using spatial correlations (seizure frequency against alpha-power shift at each channel), we found a positive correlation, particularly over frontal recording sites (Figure, right panel).



Conclusion

Correlation analysis yields qualitatively similar results to the main subgroup analyses: poorer seizure control associates with an increased shift of alpha-power to lower frequencies, particularly over frontal recordings sites.

Analysis 5: Comparing EEG recording times across groups to assess potential circadian effects.

Rationale and method

We investigated whether there were systematic differences between subgroups in the time of day at which EEG recording was carried out. This was done because it was not possible to record all EEG data during the same time of the day, and because there is well-documented interplay between circadian rhythms and seizure liability^{1,2}. To assess this, we retrieved the time stamps of each EEG recording from the raw data files, converted them from hours to radians (on a 24-hr circle) and calculated a Watson-Williams test, which compares means of circular data for two or more groups, between GSC and PSC patients (CircStat, https://github.com/circstat/circstat-matlab)³.

Results

Descriptive Statistics

Group	Circular Mean (rad.)	Circular Standard Deviation (rad.)
GSC	-2.7002	0.6427
PSC	-2.5939	0.7523

ANOVA-Table (Watson-Williams test)

	d. f.	SS		MS	F	p-Value
Columns	1	0.07	0.07	0.30	0.5861	0.5861
Residual	61	15.69	0.26			
Total	62	15.75				

d. f, degrees of freedom; SS, sum of squares; MS, mean square; F, F-statistic

Conclusion

Analysis of recording times using circular statistics shows no difference in daytime of EEG recordings between seizure control groups, thus rendering circadian effects unlikely.

Analysis 6: Additional control for anti-epileptic drug (AED) effects.

Rationale and method

We found that patients with good seizure control (GSC) were treated on average with higher doses of lamotrigine (LTG), which has been shown to accelerate alpha frequency, and might therefore *reduce* the alpha-power shift measure⁴. To test whether different LTG dosages biased between-group differences, we calculated independent samples t-test between (1) all GSC patients (n = 10) and poor seizure control (PSC) patients (n = 12) on LTG, (2) GSC patients with (n=10) and without (n=15) LTG, and (3) PSC patients with (n = 12) and without (n = 26) LTG. We hypothesised that, if the first comparison yielded a difference, but the other two did not, then the difference between groups would likely be driven by seizure control, and not by an LTG acceleration effect. Put differently, if LTG were to accelerate alpha rhythms in a measurable way in our cohort, one would expect both GSC and PSC patients on LTG to have a lower alpha-power shift (i.e. more high alpha-power) than their non-LTG counterparts. For completeness, we also compared alpha-power shifts in all patients without LTG (Test 4).

Results (Link: https://osf.io/ruvf6/)

Test 1: all GSC patients on LTG versus all PSC patients on LTG

Group Descriptives

	Group	N	Mean	SD	SE
AlphaPowerShift(log)	GSC	10	-0.160	0.212	0.067
	PSC	10	0.420	0.577	0.182

Independent Samples T-Test: all GSC patients on LTG versus all PSC patients on LTG

	Test	Statistic	df	p
AlphaPowerShift(log)	Student	-2.984	18.000	0.008
	Welch	-2.984	11.384	0.012

Test 2: GSC patients on LTG versus GSC patients without LTG

Group Descriptives

	Group	N	Mean	SD	SE	
AlphaPowerShift(log)	No	15	-0.300	0.478	0.123	
	Yes	10	-0.160	0.212	0.067	

Independent Samples T-Test

	t	df	p
AlphaPowerShift(log)	-0.866	23.000	0.395

Note. Student's t-test.

(continued on next page)

Test 3: PSC patients on LTG versus PSC patients without LTG

Group Descriptives

	Group	N	Mean	SD	SE
AlphaPowerShift(log)	No	26	0.231	0.432	0.085
	Yes	12	0.417	0.564	0.163

Independent Samples T-Test

	t	df	р
AlphaPowerShift(log)	-1.118	36.000	0.271

Note. Student's t-test.

Test 4: all GSC patients not on LTG versus all PSC patients not on LTG

Group Descriptives

	Group	N	Mean	SD	SE
AlphaPowerShift(log)	GSC	15	-0.300	0.478	0.123
	PSC	27	0.222	0.434	0.084

Independent Samples T-Test

	t	df	p
AlphaPowerShift(log)	-3.602	40.00	< .001

Note. Student's t-test.

Conclusion

This set of analyses shows that, while well-controlled patients on LTG had indeed a lower alpha-power shift compared to poorly controlled patients on LTG (Test 1), they did not differ on average from their peers without LTG (Test 2). This was replicated in the poorly controlled patients as well (Test 3), indicating that LTG did not bias our main results; i.e. LTG did not artificially reduce the alpha-power shift and therefore enhance differences between seizure control groups. This also confirmed with the last test (Test 4): patients off-LTG show the same pattern compared to those on-LTG (Test 1).

We note that small subject numbers are an important limitation, and we cannot rule out significant LTG effects on alpha power in larger or more homogeneous populations (i.e. patients in monotherapy).


Analysis 7: Topographic analysis to rule out lesional effects on spatial alpha-power shifts

Rationale and method

We show an anteriorisation of the slow alpha rhythm that is particularly pronounced in patients with focal epilepsies (see Figure 2 in the main manuscript). Because this group naturally presents a higher rate of lesional syndromes, the anteriorisation could be an epiphenomenon. To rule out this possibility, we calculated spatial permutation-based statistics (cf. Methods in main manuscript) in two subgroups without lesions: poorly controlled idiopathic generalised epilepsy (IGE, n = 10) and poorly controlled non-lesional focal epilepsy (FE, n = 11) patients, both against healthy controls.

Results

The figure below shows scalp topographic maps of family-wise error (FWE)-corrected p-values for two independent-sample t-tests of alpha-power shift: IGE patients with poor seizure control against healthy controls (left), and non-lesional FE patients with poor seizure control against healthy controls (right). In both cases, significant effects can be seen in frontal regions, although the effect is considerably stronger and has a much wider spatial distribution in FE patients.



Conclusion

This analysis shows that anteriorisation of low-frequency alpha-power in poorly controlled patients does not depend on the presence of lesions, since both IGE patients (which are per definition non-lesional) and FE patients without discernible lesions on neuroimaging show this effect. However, the magnitude of the effect is conspicuously different, either due to low statistical power or differing pathophysiological mechanisms, or both.

References

- 1. Baud MO, Kleen JK, Mirro EA, et al. Multi-day rhythms modulate seizure risk in epilepsy. Nat. Commun. 2018;9(1):88.
- 2.
- Quigg M. Circadian rhythms: interactions with seizures and epilepsy. Epilepsy Res. 2000;42(1):43–55. Berens P, Baclawski K, Berens P, Baclawski K. CircStat: A MATLAB Toolbox for Circular Statistics. J. Stat. 3. Softw. 2009;30(April):1-3.
- 4. Clemens B, Ménes A, Piros P, et al. Quantitative EEG effects of carbamazepine, oxcarbazepine, valproate, lamotrigine, and possible clinical relevance of the findings. Epilepsy Res. 2006;70(2–3):190–199.